Welcome to International Network for Natural Sciences | INNSpub

Paper Details

Research Paper | June 1, 2012

VIEWS 2
| Download

Serum adiponectin is related to resistin independent of adiposity

Ahmadi Pezhman, Torabi Mohsen, Aran Ardabili Akbar, Aghazadeh Javad

Key Words:


Int. J. Biosci.2(6), 151-158, June 2012

Certification:

IJB 2012 [Generate Certificate]

Abstract

Adipocytokines secreted by adiposity and other tissues in known to have inflammatory and anti-inflammatory property. Adiponectin and resistin are two important adipokines and they have important role in obesity and chronic related diseases. This study was designed to determine the relationship between serum adiponectin as an anti-inflammatory cytokine with resistin as a pro-inflammatory cytokine in thirty six sedentary adult men aged 38-44 years and body mass index, 32.56 ± 4.54 Kg/m2. For this purpose, participants fasted overnight to provide blood specimens and venous blood samples were collected of subjects. Blood samples were analyzed for measuring serum adiponectin and resistin. All anthropometrical variables were also measured. Serum adiponectin was not related with each anthropometrical marker (p≥0.05). In contrast, we observed that serum resistin was positively related anthropometrical indexes (p˂0.05). Serum adiponectin concentrations were negatively correlated with resistin, independent of BMI or fat tissue (P=0.000, r=0.77). Based on these data, we conclude the relationship between adiponectin and resistin levels were independent of adiposity in obese men.

VIEWS 2

Copyright © 2012
By Authors and International Network for
Natural Sciences (INNSPUB)
http://innspub.net
This article is published under the terms of the Creative
Commons Attribution Liscense 4.0

Serum adiponectin is related to resistin independent of adiposity

Ahima RS. 2000. Adipose tissue as an endocrine organ. Obesity 14(supplement 5), 242–249.

Aldhahi W, Hamdy O. 2003. Adipokines, inflammation, and the endothelium in diabetes. Current Diabetes Reports 3, 293–298.

Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J. 1999. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysical Research Communications 257, 79–83.

Bacha F, Saad R, Gungor N, Arslanian SA. 2004. Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and B-cell function. Diabetes Care 27, 547–552.

Bassols J, Ortega FJ, Moreno-Navarrete JM, Peral B, Ricart W, Fern´andez-Real JM. 2009. Study of the proinflammatory role of human differentiated omental adipocytes. Journal of Cellular Biochemistry 107(6), 1107–1117.

Gnacińska M, Małgorzewicz S, Guzek M, Lysiak-Szydłowska W, Sworczak K. 2010. Adipose tissue activity in relation to overweight or obesity. Endokrynol Pol journal 61(2), 160-8.

Hanif Wasim, Nasser M, Raja C, Phillip G, Barnett AH, Sudhesh K. 2006. Relationship of serum adiponectin and resistin to glucose intolerance and fat topography in south-Asians. Cardiovascular Diabetology 5(10), 5-10.

Hansen D, Dendale P, Beelen M, Jonkers RA, Mullens A, Corluy L. 2010. Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients. European Journal of Applied Physiology 109(3), 397-404.

Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W. 2000. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO 19, 4046–4055.

Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. 2002. Resistin gene expression in human adipocytes is not related to insulin resistance. Obesity Research 10, 1–5.

Kadowaki T, Yamauchi T, Kubota N. 2006. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. Journal of Clinical Investigation 116, 1784–1792.

Knudson JD, Payne GA, Borbouse L, Tune JD. 2008. Leptin and mechanisms of endothelial dysfunction and cardiovascular disease. Current Hypertension Reports 10, 434–439.

Kusminski CM, McTernan PG, Kumar S. 2005. Role of resistin in obesity, insulin resistance and Type II diabetes. Clinical Science (Lond) 109, 243–256.

Li Y,Wang Y, Li Q, Chen Y, Sun SZ, ZhangWD, Jia Q. 2007. Effect of resistin on vascular endothelium secretion dysfunction in rats. Endothelium 14, 207–214.

Lindsay RS, Funahashi T, Hanson RL. 2002. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360, 57–58.

Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y & Matsubara K. 1996. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochemical and Biophysical Research Communications 221, 286–289.

Martin M, Palaniappan LP, Kwan AC, Reaven GM. 2008. Ethnic differences in the relationship between adiponectin and insulin sensitivity in South Asian and Caucasian women. Diabetes Care 31, 798– 801.

McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. 2002. Resistin, central obesity, and type 2 diabetes. Lancet 359, 46–47.

McTernan PG, McTernan CL, Chetty R. 2002. Increased resistin gene and protein expression in human abdominal adipose tissue. Journal of Clinical Endocrinology & Metabolism 87, 2407.

Meilleur KG, Doumatey A, Huang H, Charles B, Chen G, Zhou J. 2010. Circulating adiponectin is associated with obesity and serum lipids in West Africans. Journal of Clinical Endocrinology & Metabolism 95(7), 3517-21.

Nagaev I., Smith U. 2001. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochemical and Biophysical Research Communications 285, 561–564.

Pajvani UB, Du X, Combs TP. 2003. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. Journal of Biological Chemistry 278, 9073–9085.

Pang SS, Le YY. 2006. Role of resistin in inflammation and inflammation-related diseases. Cellular & Molecular Immunology 3, 29–34.

Rabe K, Lehrke M, Parhofer KG, Broedl UC. 2008. Adipokines and insulin resistance. Molecular Medicine 14, 741–751.

Retnakaran R, Hanley AJG, Zinman B. 2006. Does hypoadiponectinemia explain the increased risk of diabetes and cardiovascular disease in South Asians? Diabetes Care 29, 1950–1954.

Ribot J, Rodríguez AM, Rodríguez E, Palou A. 2008. Adiponectin and Resistin Response in the Onset of Obesity in Male and Female Rats. Obesity (Silver Spring) 16(4), 723-30.

Salmenniemi U, Ruotsalainen E, Pihlajamaki J. 2004. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 110, 3842–3848.

Savage DB, Sewter CP, Klenk ES. 2001. Resistin/Fizz3 expression in  relation to obesity and peroxisome proliferator-activated receptor-γ action in humans. Diabetes 50, 2199–2202.

Scherer PE,Williams S, Fogliano M, Baldini G & Lodish HF. 1995. A novel serum protein similar to C1q, produced exclusively in adipocytes. Journal of Biological Chemistry 270, 26746–26749.

Sell H, Dietze-Schroeder D, Eckardt K, Eckel J. 2006. Cytokine secretion by human adipocytes is differentially regulated by adiponectin, AICAR, and troglitazone. Biochemical and Biophysical Research Communications 343, 700–706.

Snehalatha C, Yamuna A, Ramachandran A. 2008. Plasma Adiponectin Does Not Correlate With Insulin Resistance and Cardiometabolic Variables in Nondiabetic Asian Indian Teenagers. Diabetes Care 31(12), 2374-9.

Stefan N, Stumvoll M. 2002. Adiponectin its role in metabolism and beyond. Hormone Metabolic Research Journal 34, 469–474.

Steppan CM, Bailey ST, Bhat S. 2001. The hormone resistin links obesity to diabetes. Nature (London) 409, 307–312.

Steppan CM, Brown EJ, Wright CM. 2001. A family of tissue-specific resistin-like molecules. Proceedings of the National Academy of Sciences of the United 98, 502–506.

Tomaru T, Steger DJ, Lefterova MI, Schupp M, Lazar MA. 2009. Adipocyte-specific expression of murine resistin is mediated by synergism between peroxisome proliferator-activated receptor γ and CCAAT/enhancerbinding proteins. The Journal of Biological Chemistry 284(10), 6116–6125.

Tsao TS, Lodish HF, Fruebis J. 2002. ACRP30, a new hormone controlling fat and glucose metabolism. European Journal of Pharmacology 440, 213–221.

Weiss R, Dziura J, Burgert TS. 2004. Obesity and the metabolic syndrome in children and adolescents. New England Journal of Medicine 350. 2362–2374.

Weyer  C,  Funahashi  T,  Tanaka  S,  Hotta  K, Matsuzawa Y, Pratley RE. 2001. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. Journal of Clinical Endocrinology & Metabolism 86, 1930–1935.

Zhang J, Qin Y, Zheng X. 2002. The relationship between human serum resistin level and body fat content, plasma glucose as well as blood pressure. Zhonghua Yi Xue Za Zhi 82, 1609–1612.

SUBMIT MANUSCRIPT

Style Switcher

Select Layout
Chose Color
Chose Pattren
Chose Background